Tremendous progress has been made in the treatment of asthma over past decade. The development monoclonal antibodies against IgE, interleukin-5 (IL-5) or its receptor, IL-4 receptor particular a game changer, for selected group patients. These biologics all target allergic type 2 side spectrum asthma, but even within severe high population these drugs do not completely prevent exacerbations, re...